Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 24445718)

1.

ACP Journal Club. Review: in type 2 diabetes, dipeptidyl peptidase-4 inhibitors do not increase pancreatitis.

Morey-Vargas OL, Montori VM.

Ann Intern Med. 2014 Jan 21;160(2):JC8-9. doi: 10.7326/0003-4819-160-2-201401210-02008. No abstract available.

PMID:
24445718
2.

Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?

Xu L, Spinas GA, Niessen M.

Gastroenterology. 2011 Dec;141(6):e17. doi: 10.1053/j.gastro.2011.08.053. Epub 2011 Oct 27. No abstract available.

PMID:
22036848
3.

GLP-1-based therapies: the dilemma of uncertainty.

Spranger J, Gundert-Remy U, Stammschulte T.

Gastroenterology. 2011 Jul;141(1):20-3. doi: 10.1053/j.gastro.2011.05.019. No abstract available.

PMID:
21723985
4.

Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.

Monami M, Dicembrini I, Mannucci E.

Diabetes Obes Metab. 2014 Jan;16(1):48-56. doi: 10.1111/dom.12176. Epub 2013 Jul 28.

PMID:
23837679
5.

Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?

de Heer J, Göke B.

Expert Opin Drug Saf. 2014 Nov;13(11):1469-81. doi: 10.1517/14740338.2014.955013. Epub 2014 Oct 1. Review.

PMID:
25270593
6.

Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.

Raz I, Bhatt DL, Hirshberg B, Mosenzon O, Scirica BM, Umez-Eronini A, Im K, Stahre C, Buskila A, Iqbal N, Greenberger N, Lerch MM.

Diabetes Care. 2014 Sep;37(9):2435-41. doi: 10.2337/dc13-2546. Epub 2014 Jun 9.

PMID:
24914244
7.

Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?

Olansky L.

Cleve Clin J Med. 2010 Aug;77(8):503-5. doi: 10.3949/ccjm.77a.09167. No abstract available.

8.
9.

The safety of incretin based drugs.

Montori VM.

BMJ. 2014 Apr 24;348:g2779. doi: 10.1136/bmj.g2779. No abstract available.

PMID:
24764568
10.
11.

Preying on the pancreas? Scientists debate whether newer diabetes medications do harm.

Berg EG.

Diabetes Forecast. 2013 Oct;66(10):26, 28, 30-1. No abstract available.

PMID:
24224353
12.

One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.

Aston-Mourney K, Subramanian SL, Zraika S, Samarasekera T, Meier DT, Goldstein LC, Hull RL.

Am J Physiol Endocrinol Metab. 2013 Aug 15;305(4):E475-84. doi: 10.1152/ajpendo.00025.2013. Epub 2013 Jun 4.

13.

Saxagliptin-induced recurrent acute pancreatitis.

Lee CF, Sun MS, Tai YK.

Intern Med. 2014;53(12):1351-4. Epub 2014 Jun 15.

14.

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.

Scheen A.

Expert Opin Drug Saf. 2013 Jul;12(4):545-57. doi: 10.1517/14740338.2013.793671. Epub 2013 Apr 27. Review.

PMID:
23621381
15.

Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man.

Busch SJ, Hoffmann P, Sahota P, Johnson R, Kothny W, Meyer F, Foley JE.

Diabetes Obes Metab. 2013 Jan;15(1):72-6. doi: 10.1111/j.1463-1326.2012.01678.x. Epub 2012 Sep 9.

PMID:
22882290
16.

The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin.

Hamasaki H, Yanai H.

Int J Cardiol. 2013 Oct 3;168(3):e106. doi: 10.1016/j.ijcard.2013.07.257. Epub 2013 Aug 2. No abstract available.

PMID:
23972359
17.

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.

Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, Rios LP, Malaga G, Wong E, Sohani Z, Guyatt GH, Sun X.

BMJ. 2014 Apr 15;348:g2366. doi: 10.1136/bmj.g2366. Review.

18.

Linagliptin. Avoid gliptins!

[No authors listed]

Prescrire Int. 2013 Feb;22(135):36-7. Review. No abstract available.

PMID:
23444496
19.

Treatment with DPP-4 inhibitors does not increase the chance of pancreatitis in patients with type 2 diabetes.

Shetty AS, Nandith A, Snehalath C, Ramachandran A.

J Assoc Physicians India. 2013 Aug;61(8):543-4.

PMID:
24818338
20.

ACP Journal Club. In at-risk patients with type 2 diabetes, saxagliptin and placebo did not differ for CV events.

Morey-Vargas OL, Montori VM.

Ann Intern Med. 2014 Jan 21;160(2):JC8-9. doi: 10.7326/0003-4819-160-2-201401210-02009. No abstract available.

PMID:
24445719
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk